University of Michigan | Strategic Alliance Partners

Connect with us:

Latest from University of Michigan


Determining Which DTC Patients May Benefit from Systemic Therapy

April 26, 2024

Hyunseok Kang, MD, discusses the importance of balancing toxicities and other factors when initiating first-line treatments for patients with refractory differentiated thyroid cancer (DTC), while emphasizing the need to set clear goals and communicate potential adverse reactions before allowing patients to make informed decisions.

Dr Lin on the Effect of Perioperative Treatment on Surgical Approaches in NSCLC

September 08, 2023

Jules Lin, MD, discusses how approaches to surgical intervention in non–small cell lung cancer may have shifted with the increasing use of targeted therapy and immunotherapies in the adjuvant and neoadjuvant setting.

Dr Vaishampayan on the Use of Talazoparib and Enzalutamide in Patients With HRR Gene–Mutated mCRPC

August 24, 2023

Ulka Nitin Vaishampayan, MBBS, discusses the need for improved identification of patients with homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer who may benefit from treatment with talazoparib and enzalutamide.